In a recent decision, a D.C. federal judge upheld the U.S. Food and Drug Administration’s determination regarding a narcolepsy treatment by ruling that it is not the “same drug” as Jazz Pharmaceuticals’ exclusive treatment. This ruling supports the FDA’s approval process of the rival drug as compliant with the stipulations of the Orphan Drug Act. The case sheds light on the ongoing complexities of drug development and regulatory approvals aimed at supporting rare disease treatments. For additional details, refer to the complete article on
Law360.